Pediatric Zestril
Executive Summary
FDA approves AstraZeneca's ACE-inhibitor Zestril (lisinopril) July 1 for treatment of hypertension in children six to 16. AstraZeneca licenses the compound from Merck. The two companies had pediatric exclusivity for lisinopril products through June 29, 2002 (1"The Pink Sheet" Dec. 3, 2001, In Brief)...
You may also be interested in...
Merck/AstraZeneca lisinopril exclusivity
Merck and AstraZeneca receive pediatric exclusivity through June 29 on lisinopril products (Merck's Prinivil; AstraZeneca's Zestril and Zestoretic). The companies are seeking to have the pediatric data added to labeling; FDA is reviewing supplemental NDAs. AstraZeneca licenses lisinopril from Merck...
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.